Parnassus Investments, an investment management company, released the “Parnassus Core Equity Fund” fourth quarter 2024 ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Buying $100 In VRTX: If an investor had bought $100 of VRTX stock 5 years ago, it would be worth $253.80 today based on a ...

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) was upgraded by analysts at StockNews.com from a “hold” rating to a ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

Shares of Vertex Pharmaceuticals Inc. VRTX rose 1.45% to $495.42 Wednesday, on what proved to be an all-around mixed trading session for the stock market, with the S&P 500 Index SPX rising 0.49% to ...

The past decade has been a game-changing one for Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech won approval for its first cystic fibrosis (CF) drug -- Kalydeco -- back in 2012 and has since ...

On March 7, 2025, Vertex Pharmaceuticals announced that its cystic fibrosis treatment, ALYFTREK®, had received regulatory approval from the UK's MHRA, a significant milestone in expanding its ...

In the latest market close, Vertex Pharmaceuticals (VRTX) reached $502.92, with a +1.51% movement compared to the previous day. The stock outperformed the S&P 500, which registered a daily loss of ...

Vertex Pharmaceuticals Stock Up 0.5 % Vertex Pharmaceuticals stock opened at $488.29 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.35 and a current ratio of 2.69 ...

In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $495.29, marking a +1.42% move from the previous day. The stock outperformed the S&P 500, which registered a daily gain of 0.49%.

Try Now>> See the top stocks recommended by analysts >> Read More on VRTX: Vertex Pharmaceuticals NewsMORE Related Stocks Indices Commodities Currencies Stocks ...